Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; ...
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free s...
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that...
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display,...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or r...
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new t...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability ...
– The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-fr...
